File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial

TitleRabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial
Authors
KeywordsDouble-Blind
Laryngopharyngeal Reflux
Proton Pump Inhibitor
Rabeprazole
Issue Date2010
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2010, v. 8 n. 9, p. 770-776 How to Cite?
AbstractBackground & Aims: There is controversy about the efficacy of treating patients with laryngopharyngeal reflux (LPR) using proton pump inhibitors (PPIs). We assessed the effects of high doses of the PPI rabeprazole in patients with LPR. Methods: Patients with LPR symptoms were assigned randomly to receive rabeprazole (20 mg, twice daily, n = 42) or placebo (n = 40) for 12 weeks. All patients completed symptom questionnaires; these provided demographic information and the reflux symptom index before, during, and 6 weeks after cessation of treatment. Videolaryngostroboscopy was used to document the laryngeal findings and determine the reflux finding score. Results: Twenty-four patients (57.1%) in the rabeprazole group and 27 patients (67.5%) in the placebo group had pH-documented LPR. The total reflux symptom index score decreased significantly in the group given rabeprazole, compared with patients given placebo, at weeks 6 and 12, but not at week 18. However, there were no significant differences in reflux finding scores between the rabeprazole and placebo groups at any of the time points. Conclusions: Twelve weeks of treatment with rabeprazole (20 mg, twice daily) significantly improved reflux symptoms, compared with placebo, in patients with LPR. Relapse of symptoms was observed 6 weeks after stopping PPI therapy, indicating the requirement for longer treatment duration in patients with LPR. © 2010 AGA Institute.
DescriptionComment in Clin Gastroenterol Hepatol. 2010 Sep;8(9):741-2
Persistent Identifierhttp://hdl.handle.net/10722/132470
ISSN
2015 Impact Factor: 7.68
2015 SCImago Journal Rankings: 2.744
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, PKYen_HK
dc.contributor.authorNg, MLen_HK
dc.contributor.authorCheung, TKen_HK
dc.contributor.authorWong, BYHen_HK
dc.contributor.authorTan, VPYen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2011-03-28T09:25:03Z-
dc.date.available2011-03-28T09:25:03Z-
dc.date.issued2010en_HK
dc.identifier.citationClinical Gastroenterology And Hepatology, 2010, v. 8 n. 9, p. 770-776en_HK
dc.identifier.issn1542-3565en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132470-
dc.descriptionComment in Clin Gastroenterol Hepatol. 2010 Sep;8(9):741-2-
dc.description.abstractBackground & Aims: There is controversy about the efficacy of treating patients with laryngopharyngeal reflux (LPR) using proton pump inhibitors (PPIs). We assessed the effects of high doses of the PPI rabeprazole in patients with LPR. Methods: Patients with LPR symptoms were assigned randomly to receive rabeprazole (20 mg, twice daily, n = 42) or placebo (n = 40) for 12 weeks. All patients completed symptom questionnaires; these provided demographic information and the reflux symptom index before, during, and 6 weeks after cessation of treatment. Videolaryngostroboscopy was used to document the laryngeal findings and determine the reflux finding score. Results: Twenty-four patients (57.1%) in the rabeprazole group and 27 patients (67.5%) in the placebo group had pH-documented LPR. The total reflux symptom index score decreased significantly in the group given rabeprazole, compared with patients given placebo, at weeks 6 and 12, but not at week 18. However, there were no significant differences in reflux finding scores between the rabeprazole and placebo groups at any of the time points. Conclusions: Twelve weeks of treatment with rabeprazole (20 mg, twice daily) significantly improved reflux symptoms, compared with placebo, in patients with LPR. Relapse of symptoms was observed 6 weeks after stopping PPI therapy, indicating the requirement for longer treatment duration in patients with LPR. © 2010 AGA Institute.en_HK
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_HK
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_HK
dc.subjectDouble-Blinden_HK
dc.subjectLaryngopharyngeal Refluxen_HK
dc.subjectProton Pump Inhibitoren_HK
dc.subjectRabeprazoleen_HK
dc.titleRabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.emailNg, ML: manwa@hku.hken_HK
dc.identifier.emailTan, VPY: vpytan@hku.hken_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityNg, ML=rp00942en_HK
dc.identifier.authorityTan, VPY=rp01458en_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.cgh.2010.03.009en_HK
dc.identifier.pmid20303417-
dc.identifier.scopuseid_2-s2.0-77956171980en_HK
dc.identifier.hkuros185211-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956171980&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue9en_HK
dc.identifier.spage770en_HK
dc.identifier.epage776en_HK
dc.identifier.isiWOS:000281893100009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLam, PKY=7202366058en_HK
dc.identifier.scopusauthoridNg, ML=15923631600en_HK
dc.identifier.scopusauthoridCheung, TK=7103334158en_HK
dc.identifier.scopusauthoridWong, BYH=7402023295en_HK
dc.identifier.scopusauthoridTan, VPY=24449627600en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats